Furthermore, the biologic basis of the discrepancy in clinical outcomes with the mismatch repair deficiency conferring worse survival in primary IDH-mutant astrocytomas versus more favorable survival in primary IDH-wildtype glioblastomas compared to their respective non-hypermutant counterparts remains uncertain. This evidence concerns the gene IDH2 and glioblastoma.